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LETTERS TO THE EDITOR
Regarding “Radiocephalic and brachicephalic
arteriovenous fistula outcomes in the elderly”
We read with great interest the article by Weale et al,1 quoting
also our meta-analysis bringing up the controversial topic of access
selection in the elderly.2 We fully agree with their statement that
“patients over 65 years of age suitable for any form of surgical
access should not automatically be offered a brachial-cephalic arterio-
venous fistula (BCAVF) as a first access procedure” and their insis-
tence to use radial-cephalic arteriovenous fistulas (RCAVF) in those
patients in whom it appears clinically appropriate. The authors, how-
ever, challenged our finding that elderly patients have significant
benefit from BCAVF compared with RCAVF in terms of one-year
failure rate, commenting that the latter had not been upheld by their
data for either the group aged 65 to 79 years or the over 80 group. In
an effort to renovate our data, we added in our meta-analysis the data
of Weale et al regarding the one-year secondary patency of BCAVF
and RCAVF in elderly patients (in both groups; those aged 65 to 79
years or aged over 80). A total of 317 patients over 65 years of age
were added (167 out of them underwent RCAVF and 150 BCAVF
respectively).
The meta-analysis results after adding the relevant data ex-
tracted from the article of Weale et al are depicted in the figure.
The pooled effect was presented as odds ratio and 95% confidence
intervals (OR and 95% CI) representing the odds of failure at one year
in the BCAVF group as compared with the RCAVF group. The OR
was 0.62 (95% CI 0.46-0.83, fixed effect model) in favor of a BCAVF,
indicating that the risk of failure of BCAVFs at one year is significantly
less than RCAVFs in elderly patients over 65 years of age, a trend that
was also noticed and in the article of Weale et al.
We agree that the existing literature where our meta-analysis
was based includes only non-randomized studies and therefore the
pooled data from those cannot provide level one evidence. How-
ever, in elderly patients conservation of proximal access sites are of
minimal importance because of their limited life expectancy and
more liberal use of proximal access types as the BCAVF is in our
view justified; such a choice may also be beneficial in terms of
one-year failure rate as was clearly indicated in the pooled results of
all the existing studies up to now (Fig).
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Reply
We are encouraged that the authors of the recent meta-
analysis of arteriovenous fistulas (AVFs) in the elderly agree that
patients suitable for radiocephalic fistulas should be offered that
procedure, regardless of age.1
However, we do not agree that the simple addition of our data
to the meta-analysis is helpful or strengthens the argument against
radiocephalic fistulas in the over 65s. In the original meta-analysis,
the authors analyzed the results from four studies that compared
outcomes between radiocephalic and brachiocephalic AVFs in the
elderly: three were retrospective,2-4 and one has not been pub-
lished in a peer reviewed journal.5 The three trials in the peer
review literature vary widely in terms of quality and consistency of
methodologic reporting.
However, most damaging to the validity of the meta-analysis is
the fact that the patient populations in each study are radically
different: Lok et al2 (as in our study) report only consecutive “first
attempted” AVF outcomes; in the study by Kawecka et al,4 it is not
clear whether the outcomes of secondary or tertiary fistulas are
included in reported patency rates; finally, the Berardinelli and
Vegeto3 study reports the outcome only of patients in their hands
who have previously had “multiple failed attempts” to surgically
create access in other centers (mean, 3.4 prior procedures). It is
perhaps unsurprising that they observed that forearm AVFs are
used at a low rate (32 of 494) and perform worse (12 of 32 failed)
than brachiocephalic AVF (221 of 494, with 18 failures) in such a
population. It is this study of tertiary access that has skewed the
results of the meta-analysis, and those re-reported above, towards
lower failure rates with brachiocephalic compared with radioce-
phalic AVF in the elderly.
Furthermore the authors have suggested that conservation of
proximal access sites is not important because of limited life expect-
ancy in the over 65s. A recent Canadian study6 has observed that 3-
and 5-year survival in the over 65s is 51.5% and 33.5%, respectively,
and continues to improve despite increasing comorbidity. We
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Fig. Forest plot compares the odds ratio (and 95% confidence
intervals) of the one-year failure rate of BBAVF and RCAVF in
elderly patients over 65 years of age. The effect of individual studies
is demonstrated with red squares and the pooled effect (OR 0.62,
CI 0.46-0.83) is demonstrated with a yellow rhombus.
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would argue that such a life expectancy is certainly long enough
not to simply disregard the radiocephalic fistula.
Andy Robert Weale, MRCS
Surgery, Southmead Hospital
Bristol, Avon, United Kingdom
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Regarding “Stenting for femoropopliteal lesions”
We have read with interest the article by Mwipatayi et al1 on
the contemporary topic of femoropopliteal stenting. Unfortu-
nately, the authors’ conclusion that stent placement for treatment
of femoropopliteal disease does not increase patency at 1 year
compared with balloon angioplasty alone is flawed by several
unacceptable limitations of this meta-analysis.
Clinical heterogeneity of the included studies is the most
relevant drawback: First, different types of stents (balloon-
expanding stainless steel stents, self-expanding Elgiloy stents, self-
expanding Nitinol stents, and polytetrafluoroethylene-covered stent
grafts) were included in the analysis. Each of these devices has
fundamentally differential characteristics, indications, and out-
comes, and therefore cannot be summarized as one category.2
Second, seven prospective randomized studies were mixed with
the results of a retrospective and purely observational study. Par-
ticularly, the latter study was of extremely poor quality without
standardized follow-up intervals (follow-up ranged from 1 to 72
months). Third, clinical characteristics of patients treated within
the studies were highly variable: Balloon-expanding stents can be
used for only very short lesions (spot stenting), whereas stent grafts
and self-expanding stents are implanted for longer lesions. Because
of this selection bias, it is impossible to assess whether stents may
have beneficial effects in certain predefined subgroups (eg, patients
with long lesions or total occlusions). Fourth, treatment strategies
within the different trials were not consistent: six randomized
studies including short lesions compared primary stenting vs bal-
loon angioplasty alone. In contrast, one study that also included
longer lesions compared primary stenting vs balloon angioplasty
with optional secondary stenting.3
In Table 1 restenosis and patency rates of the ABSOLUTE
trial3 at 12 months are mixed up (the table reports 63% patency
rate, which should read 37%). This overestimation may have sig-
nificantly influenced the pooled risk estimates.
Addressing the issue of stent fractures, six of the eight studies
did not systematically assess stent fractures; therefore, this end
point should not be reported.
Finally, a cut off for including studies published later than the
year 2000 is by no scientific means justified. A major change in
stent technology was seen in 2004 and 2005 when the first
promising data on Nitinol stents were reported. From our point of
view, a clinically reasonable meta-analysis should include only data
from randomized controlled trials comparing Nitinol stents vs
balloon angioplasty, that is, findings from the ABSOLUTE,3
FAST,4 and RESILIENT trials.
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Reply
The drawbacks of our study were addressed in the discussion
portion of our paper.
1. We were unable to acquire missing data from the authors of
included studies. The clinical heterogeneity of the included
studies was a relevant drawback because those studies were
conducted by different authors; these authors may not have
included data according to the Society for Vascular Surgery/
International Society for Cardiovascular Surgery (SVS/ISCS)
standard of reporting, thus affecting the results of the meta-
analysis.
2. A sensitivity analysis was performed that excluded studies that
might influence the final result. It did not change the findings of
our meta-analysis.
3. In the Design/Methods section of our paper, we clearly defined
re-stenosis and primary patency. Re-stenosis and patency rates
were not mixed in Table 1. Unfortunately, reporting inconsis-
tencies occurred in all studies. Some authors included restenosis
rate and others reported primary patency.
4. We agree that the issue of stent fractures cannot be reported as
an end point: We did, however, include the results of the few
studies that reported stent fractures because we have reported
our own experience in another area (carotid stenting).
5. Data for this study were collected from September 2000 and
January 2007, and Absolute and Fast were included. The
Resilient results were not available at that time. We were
amenable to the inclusion of studies that did use new stent
technology.
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